Behavioral stress accelerates prostate cancer development in mice

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 874-886

  Hassan, Sazzad ^a   Karpova, Yelena ^a   Baiz, Daniele ^a   Yancey, Dana ^a   Pullikuth, Ashok ^a   Flores, Anabel ^a   Register, Thomas ^a   Cline, J Mark ^a   D'agostino, Ralph ^a   Danial, Nika ^b   Datta, Sandeep Robert ^c   Kulik, George ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BICALUTAMIDE; CASPASE 3; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIORAL STRESS; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MENTAL STRESS; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

EID: 84873358810     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI63324     Document Type: Article

References (61)

1. Berkow SE, Barnard ND, Saxe GA, Ankerberg-Nobis T. Diet and survival after prostate cancer diagnosis. Nutr Rev. 2007;65(9):391-403.
2. Saxe GA, Major JM, Nguyen JY, Freeman KM, Downs TM, Salem CE. Potential attenuation of disease progression in recurrent prostate cancer with plant-based diet and stress reduction. Integr Cancer Ther. 2006;5(3):206-213.
3. Ornish D, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008;105(24):8369-8374.
4. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003;54(3):269-282.
5. Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. Neuroendocrine modulation of cancer progression. Brain Behav Immun. 2009;23(1):10-15.
6. Ullrich PM, Carson MR, Lutgendorf SK, Williams RD. Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J Urol. 2003;169(4):1449-1452.
7. Cohen L, et al. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program. Cancer Epidemiol Biomarkers Prev. 2003;12(7):610-617.
8. Stone AA, Mezzacappa ES, Donatone BA, Gonder M. Psychosocial stress and social support are associated with prostate-specific antigen levels in men: results from a community screening program. Health Psychol. 1999;18(5):482-486.
9. Miller HC. Stress prostatitis. Urology. 1988;32(6):507-510.
10. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004;15(6):535-541.
11. Sastry KS, et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem. 2007;282(19):14094-14100.
12. Palm D, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by betablockers. Int J Cancer. 2006;118(11):2744-2749.
13. Yemelyanov A, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene. 2007;26(13):1885-1896.
14. Datta SR, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell. 2002;3(5):631-643.
15. Parker J, et al. Chronic stress accelerates ultravioletinduced cutaneous carcinogenesis. J Am Acad Dermatol. 2004;51(6):919-922.
16. Thaker PH, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939-944.
17. Thalmann GN, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate. 2000;44(2):91-103.
18. Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
19. Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy [published online ahead of print July 20, 2012]. Prostate. doi:10.1002/pros.22564.
20. Nagmani R, Pasco DS, Salas RD, Feller DR. Evaluation of beta-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP. Biochem Pharmacol. 2003;65(9):1489-1494.
21. Samama P, Pei G, Costa T, Cotecchia S, Lefkowitz RJ. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. Mol Pharmacol. 1994;45(3):390-394.
22. Sastry KS, Smith AJ, Karpova Y, Datta SR, Kulik G. Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD. J Biol Chem. 2006;281(30):20891-20901.
23. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 2005;8(4):287-297.
24. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X (L). Cell. 1996;87(4):619-628.
25. Harada H, et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell. 1999;3(4):413-422.
26. Cole SW, Sood AK. Molecular pathways: betaadrenergic signaling pathways in cancer. Clin Cancer Res. 2012;18(5):1201-1206.
27. Shaywitz AJ, Greenberg ME. CREB: a stimulusinduced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 1999;68:821-861.
28. Guo M, et al. Cytokines regulate beta-2-adrenergic receptor responsiveness in airway smooth muscle via multiple PKA-and EP2 receptor-dependent mechanisms. Biochemistry. 2005;44(42):13771-13782.
29. Ellwood-Yen K, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 2003;4(3):223-238.
30. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27(50):6462-6472.
31. So AI, Hurtado-Coll A, Gleave ME. Androgens and prostate cancer. World J Urol. 2003;21(5):325-337.
32. Scattoni V, et al. Pathological changes of highgrade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU Int. 2006;98(1):54-58.
33. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl. 1992;13(6):457-464.
34. Nickerson T, Pollak M. Bicalutamide (Casodex) - induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology. 1999;54(6):1120-1125.
35. Danial NN. BAD: undertaker by night, candyman by day. Oncogene. 2008;7(suppl 1):S53-S70.
36. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34-45.
37. Kasbohm EA, et al. Androgen receptor activation by G (s) signaling in prostate cancer cells. J Biol Chem. 2005;280(12):11583-11589.
38. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via crosstalk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem. 1999;274(12):7777-7783.
39. Blok LJ, De Ruiter PE, Brinkmann AO. Forskolininduced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry. 1998;37(11):3850-3857.
40. Fu M, et al. The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem. 2004;279(28):29436-29449.
41. Selye H. The Stress of Life. New York, New York, USA: McGraw-Hill; 1956.
42. Ben Eliyahu S, Page GG, Schleifer SJ. Stress, NK cells, and cancer: Still a promissory note. Brain Behav Immun. 2007;21(7):881-887.
43. Sloan EK, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70(18):7042-7052.
44. Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Semin Cancer Biol. 2008;18(3):164-170.
45. Ramberg H, et al. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008;68(10):1133-1142.
46. Gousse A, Yoshida M, Weiss RM, Latifpour J. Beta adrenergic receptor alterations in diabetic rat prostate: effects of insulin and dietary myoinositol. Prostate. 1991;19(2):121-131.
47. Cao L, et al. Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell. 2010;142(1):52-64.
48. Poyet P, Gagne B, Labrie F. Characteristics of the beta-adrenergic stimulation of adenylate cyclase activity in rat ventral prostate and its modulation by androgens. Prostate. 1986;9(3):237-245.
49. Krajewska M, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003;9(13):4914-4925.
50. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur Cytokine Netw. 2001;12(4):654-663.
51. Yu J, et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 2007;12(5):419-431.
52. Prowatke I, et al. Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer. 2007;96(1):82-88.
53. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer. 2010;1(6):617-628.
54. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004; (32): 57-71.
55. Shahzad MM, et al. Stress effects on FosB-and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010;285(46):35462-35470.
56. Sood AK, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010;120(5):1515-1523.
57. Hara MR, et al. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature. 2011;477(7364):349-353.
58. Feng Z, et al. Chronic restraint stress attenuates p53 function and promotes tumorigenesis. Proc Natl Acad Sci U S A. 2012;109(18):7013-7018.
59. Datta SR, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91(2):231-241.
60. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1997;17(3):1595-1606.
61. Baiz D, et al. Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug. J Med Chem. 2012;55(18):8038-8046.